Literature DB >> 1449922

Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function.

D B Northridge1, A Jardine, E Henderson, S G Dilly, H J Dargie.   

Abstract

OBJECTIVE: +/- Candoxatrilat was used to raise atrial natriuretic factor (ANF) concentrations in patients with heart failure, and the effects on left ventricular systolic and diastolic function were studied to determine the contribution of peripheral and central mechanisms to the haemodynamic effects.
DESIGN: This was a single blind, randomised comparison of +/- candoxatrilat and placebo in patients with mild heart failure. All patients received two intravenous doses of +/- candoxatrilat and two placebo doses on four consecutive days.
SETTING: A teaching hospital department of cardiology. PATIENTS: Six men (mean age 52 years) with mild heart failure (New York Heart Association class II) due to ischaemic heart disease (four patients) or dilated cardiomyopathy (two patients) were included. Mean ejection fraction was 37.5% and mean peak oxygen consumption was 20.4 ml/min/kg. MAIN OUTCOME MEASURES: Plasma ANF concentrations, haemodynamic indices and left ventricular diastolic function measured by early to atrial filling rate (E:A ratio) with Doppler echocardiography were determined before and after +/- candoxatrilat and placebo.
RESULTS: +/- Candoxatrilat caused a threefold rise of plasma ANF compared with placebo (p < 0.005), but there was no significant change in heart rate, blood pressure, or cardiac output. Mean right atrial pressure fell from 6.7 to 4.7 mmHg (NS) and pulmonary artery wedge pressure fell from 9.2 to 6.7 mmHg (p < 0.05). Doppler echocardiographic measurements of transmitral blood flow showed a significant fall in peak early left ventricular filling velocity from 39.5 to 34.2 cm/s (p < 0.05), along with a non-significant rise in peak atrial filling velocity from 39.7-41.6 cm/s after +/- candoxatrilat. The E:A ratio, a Doppler index of left ventricular diastolic function, fell from a mean of 1.04 to 0.87 (p < 0.05).
CONCLUSIONS: +/- Candoxatrilat increased plasma ANF concentrations and reduced right atrial and pulmonary artery wedge pressures. No evidence of an improvement in left ventricular systolic or diastolic function was found, so the fall in preload was due to peripheral effects, either an increase in venous capacitance or a fall in circulating blood volume.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1449922      PMCID: PMC1025138          DOI: 10.1136/hrt.68.10.387

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  16 in total

1.  Effects of atrial natriuretic factor on coronary hemodynamics and myocardial energetics in patients with heart failure.

Authors:  H C Herrmann; I F Palacios; G W Dec; J M Scheer; M A Fifer
Journal:  Am Heart J       Date:  1988-06       Impact factor: 4.749

2.  Influence of aging on Doppler echocardiographic indices of left ventricular diastolic function.

Authors:  P Spirito; B J Maron
Journal:  Br Heart J       Date:  1988-06

Review 3.  Cyclic guanosine monophosphate as a mediator of vasodilation.

Authors:  F Murad
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

4.  Direct effect of alpha-human atrial natriuretic peptide on human vasculature in vivo and in vitro.

Authors:  A Hughes; S Thom; P Goldberg; G Martin; P Sever
Journal:  Clin Sci (Lond)       Date:  1988-02       Impact factor: 6.124

5.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats.

Authors:  A J de Bold; H B Borenstein; A T Veress; H Sonnenberg
Journal:  Life Sci       Date:  1981-01-05       Impact factor: 5.037

6.  Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure.

Authors:  D B Northridge; A G Jardine; I N Findlay; M Archibald; S G Dilly; H J Dargie
Journal:  Am J Hypertens       Date:  1990-09       Impact factor: 2.689

7.  The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.

Authors:  A G Jardine; J M Connell; D Northridge; S G Dilly; N J Cussans; G Davidson; J Doyle; B L Leckie; A F Lever
Journal:  Am J Hypertens       Date:  1990-09       Impact factor: 2.689

8.  Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods.

Authors:  A M Richards; G Tonolo; G D McIntyre; B J Leckie; J I Robertson
Journal:  J Hypertens       Date:  1987-04       Impact factor: 4.844

9.  Haemodynamic effects of atrial peptide infusion in heart failure.

Authors:  I G Crozier; M G Nicholls; H Ikram; E A Espiner; H J Gomez; N J Warner
Journal:  Lancet       Date:  1986-11-29       Impact factor: 79.321

10.  Vascular responses to local atrial natriuretic peptide infusion in man.

Authors:  D J Webb; N Benjamin; M J Allen; J Brown; M O'Flynn; J R Cockcroft
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

View more
  1 in total

Review 1.  The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases.

Authors:  Angelino Calderone
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.